MAIA reports 88% disease control rate in expanded Phase 2 THIO-101 lung cancer trial
Combined data from Parts A, B and C of the ateganosine study in third-line NSCLC show consistent efficacy as the patient pool grows, MAIA said.
SEC filing
1 story
Combined data from Parts A, B and C of the ateganosine study in third-line NSCLC show consistent efficacy as the patient pool grows, MAIA said.
SEC filing